// App-Quantinova.ai

: A prospective phase II trial of pembrolizumab plus lenvatinib in advanced adrenal cortical carcinoma after failure of platinum- and mitotane-based chemotherapy (ACCOMPLISH).

Researchers

Presenter

  • Inkeun Park

Principal Investigators

  • Minsuk Kwon

  • Kwonoh Park

  • Se Hoon Park

  • Joo-Hwan Park

  • Sang Joon Shin

  • Hyun-Jeong Shim

  • Tak Yun

  • Jae-Lyun Lee

  • Hyo Jin Lee

  • Wonyoung Choi

Medical Centers

  • Ajou University Medical Center, Suwon, South Korea

  • Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Center for Rare Cancer, National Cancer Center, Ilsandong-Gu,Goyang-Si, South Korea

  • National Cancer Center, Goyang-si, Korea

  • Gachon University Gil Hospital, Incheon, Korea

  • Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea

  • Samsung Medical Center, Sungkyunkwan Univ., Gangnam-Gu, South Korea

  • (1) Pusan National University Yangsan Hospital, Yangsan, Korea

  • Chonnam National University Hwasun Hospital, Hwasun,

Locations

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Cardiovascular (CVS)

Disease

  • Hypertension

  • Solid malignancies

Biomarkers

  • Acetyl-CoA carboxylase

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

  • Cisplatin

  • Lysodren

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT05036434

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved